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1. Abstract 
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by 
autoimmune-mediated inflammation, demyelination, and lesion formation in the central nervous 
system (CNS). FTY720, a structural analogue of the endogenous sphingolipid, sphingosine, has 
been discovered as an orally-available immunomodulator effective at treating MS. FTY720-
phosphate (FTY720P), the phosphorylated form of FTY720, resembles sphingosine-1-phosphate 
(S1P), and is a potent ligand on four out of the five S1P receptors. This investigation used a 
qualitative systems biology approach, aided by the computer modeling tool, CellDesigner, to 
create computational signaling models of the S1P receptors and of cell types that are involved in 
the observed FTY720P-mediated neuroprotection in MS. These models were used to explore the 
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actions of S1P and FTY720P on the S1P receptors in different cell types and to test the ability of 
the models to qualitatively reproduce results in the literature. While the S1P receptor and cell 
type models were not perfect in a quantitative sense, they succeeded in qualitatively reproducing 
events described in the literature. 
 
2. Overview of Multiple Sclerosis 
Multiple sclerosis (MS) is a chronic neurodegenerative disease characterized by 
autoimmune-mediated inflammation, demyelination, and lesion formation in the central nervous 
system (CNS). MS is the leading cause of neurological disability in young adults, affecting more 
than 2.5 million people worldwide (Weinshenker 1996), with most people diagnosed between the 
ages of 20 and 40 (Kuby et al., 2007).  
While the pathogenesis and mechanisms of lesion formation in MS are poorly 
understood, researchers understand that MS is an autoimmune disease impacting myelin, a fatty 
substance rich in lipids and proteins (National MS Society, 2008). Myelin is created by 
oligodendrocytes (ODCs) and surrounds and protects nerve fibers in the CNS, facilitating the 
transmission of electrochemical messages between the brain, spinal cord, and other parts of the 
body. During an MS attack, an abnormal immune reaction initiates the proliferation and 
activation of autoreactive, myelin-specific T lymphocytes. These lymphocytes express adhesion 
molecules which cause changes in endothelia and allow the lymphocytes access into the CNS via 
the blood-brain barrier (BBB) (Compston and Coles, 2002), a semi-permeable, selective barrier 
between the blood and the CNS composed of endothelial cells. Once across the BBB, the T 
lymphocytes recognize endogenous antigens presented locally by microglia and/or astrocytes, 
resulting in local amplification of pro-inflammatory cytokines and chemokines (McQualter and 
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Bernard, 2007). These pro-inflammatory cytokines and chemokines activate other inflammatory 
cells, including cytotoxic T lymphocytes, B lymphocytes and macrophages, which are thought to 
be directly involved in demyelination and the formation of lesions along nerves.  
Demyelination is also associated with loss of ODCs and axonal injury at lesion sites 
(Matute and Pérez-Cerdá, 2005). The disruption of nerve impulses at lesion sites impedes 
communication between the brain, spinal cord, and other parts of the body, resulting in the 
neurological symptoms associated with MS. These symptoms vary from person to person and 
depend on which nerve fibers are affected. Common symptoms include fatigue, numbness, 
coordination problems, bladder and bowel dysfunction, vision problems, and dizziness (National 
MS Society, 2008).  
2.1 Etiology of MS  
The etiology of MS is currently unknown, but there is evidence that many factors may be 
involved. These include gender, genetics, age, geography, ethnic background, and exposure to 
viral infection. For example, genetic studies show that the risk of developing MS in the general 
population is 1 in 750. This risk rises to 1 in 40 for anyone who has a close relative (parent, 
sibling, or child) with the disease (National MS Society, 2008). Although a gene has not been 
linked to MS, these findings suggest that a genetic predisposition could cause some individuals 
to be more likely to develop MS than others. Interestingly, MS occurs more frequently in people 
living in areas farther from the equator, suggesting that there may be an environmental trigger 
involved (National MS Society, 2008). Finally, viral infections may be linked to the development 
of MS; associations have been found between MS and two viruses, human herpes virus 6 and 
Epstein-Barr virus (Solden et al., 1997; Ascherio, 2001). While there is evidence of the 
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involvement of many factors in the development of MS, the cause of MS is far from understood 
and is the target of millions of dollars in research each year.  
2.2 Treatments for MS 
There is currently no cure for MS. However, there are several FDA-approved 
medications used to modify the course of the disease or to manage its symptoms. Beta-
interferons, which include interferon-beta-1a (Avonex, Rebif) and interferon-beta-1b 
(Betaseron), are a category of drugs commonly used to treat relapsing-remitting MS (RR-MS). 
RR-MS is one of four recognized disease courses of MS and involves clearly defined attacks of 
worsening neurological function followed by partial or complete recovery. Eighty-five percent of 
the time, RR-MS is the initial diagnosis of MS (National MS Society, 2008). The exact 
mechanism of action of beta-interferons in MS patients is unknown, but it is believed to reduce 
inflammation by reducing the expression of MHC class II molecules, thereby decreasing antigen 
presentation, decreasing apoptosis, and reducing the expression of cell adhesion molecules 
(Trapp and Nave, 2008). Overall, these effects decrease the entry of immune cells into the CNS.  
Another drug commonly used to treat RR-MS is glatiramer acetate (Copaxone), which is 
a polymer of naturally occurring amino acids that are found in myelin basic protein, a protein 
involved in myelination of nerves in the CNS. Glatiramer acetate reduces inflammation by 
decreasing antigen presentation and stimulating the secretion of anti-inflammatory cytokines by 
T lymphocytes (Neuhaus et al., 2001).  
Unfortunately, medications used to treat MS have a limited clinical effect and often 
produce unwanted side effects. Conventional first-line drugs for MS have an average relapse rate 
of 30–35% in two-year studies (Jacobs et al., 1996). In addition, these drugs require frequent 
injections, either subcutaneously or intramuscularly. Patient surveys have shown that the main 
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obstacles to initiating and maintaining MS therapy are the patient’s fear of needles and the 
inconvenience of frequent injections (NOP, 2004).  
 
3. Introduction to FTY720 
 FTY720 (fingolimod), a structural analogue of the endogenous sphingolipid, sphingosine, 
has been discovered as an orally-available immunomodulator effective at treating MS. 
Preliminary results from Phase III clinical trials released in December 2008 showed that 
treatment with FTY720 reduces relapse rates in MS patients by 52% compared to a current first-
line drug, Avonex (Novartis, 2008). FTY720, first synthesized by Novartis in 1992, was derived 
by chemical modification of myriocin, a metabolite of the parasitic fungus Isaria sinclairii. 
FTY720 acts as an immunomodulator, sequestering T lymphocytes from the blood into the 
lymph nodes (Chiba et al., 1998).  
 FTY720, like sphingosine, can be phosphorylated in vivo by sphingosine kinase (SphK) 
(Figure 1).  FTY720-phosphate (FTY720P), the phosphorylated form of FTY720, resembles 
sphingosine-1-phosphate (S1P), and is a potent ligand on four out of the five S1P G-protein 
coupled receptors (GPCRs). FTY720P displaces S1P binding with a 50% maximal inhibitory 
concentration (IC50) in picomolar range for S1P1 and S1P5 and in nanomolar range for S1P3 and 
S1P4 (Rosen et al., 2003). FTY720P is entirely inactive on S1P2. While FTY720P is a potent 
ligand for S1P1, S1P3, S1P4, and S1P5, unphosphorylated FTY720 is very weak ligand on 
S1P1, S1P2, S1P3, S1P4, and S1P5 (Table 1), indicating that FTY720 is a prodrug and 
FTY720P is its functional form.  
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Figure 1. Phosphorylation of sphingosine and FTY720 by sphingosine kinase.  
 
Table 1.  Summary of S1P receptors.  
 S1P1 S1P2 S1P3 S1P4 S1P5 
Primary 
cellular 
distribution 
(Horga and 
Montalban, 
2008): 
Lymphocytes, 
thymocytes, 
mast cells, 
eosinophils, 
VSMCs, 
GSMCs, 
neurons, 
astrocytes, 
OPCs/ODCs 
VSMCs, 
GSMCs, 
neurons 
ECs, VSCMs,  
neurons, 
astrocytes,  
OPCs/ODCs 
Lymphocytes  OPCs/ODCs 
Couples to 
(Taha et al., 
2004): 
Gi Gi, Gq, G12/13 Gi, Gq, G12/13 Gi, G12/13 Gi, G12/13 
Kd S1P (nM) 
• 8–13 (Anliker 
and Chun, 
2004) 
• 8 (transfected  
HEK 293, Lee 
et al., 1996) 
• 13.2 
(transfected 
CHO, Kon et 
al., 1999) 
• 20–27 
(Anliker and 
Chun, 2004) 
• 27 
(transfected 
HEK 293, 
Van Brockyln 
et al., 1999) 
• 20.4 
(transfected 
CHO, Kon et 
al., 1999) 
• 23–26 
(Anliker and 
Chun, 2004) 
• 23 
(transfected 
HEK 293, 
Van Brockyln 
et al., 1999) 
• 26.2 
(transfected 
CHO, Kon et 
al., 1999) 
• 13–63 
(Anliker and 
Chun, 2004) 
• 12.8–19.1 
(transfected 
CHO, 
Yamazaki et 
al., 2000) 
• 12–14.7 
(transfected 
K562, 
Yamazaki et 
al., 2000) 
• 2–10 (Anliker 
and Chun, 
2004) 
• 2 (transfected 
HEK 293, Im 
et al., 2000) 
• 2 (transfected 
Rh7777, Im et 
al., 2000) 
Kd FTY720P 
(nM) 
(Brinkmann et 
al., 2002) 
0.3 >10,000 3.1 0.6 0.3 
Kd: dissociation constant; VSMC: vascular smooth muscle cell; GSMC: gastrointestinal smooth muscle cell; ODC: 
oligodendrocyte; OPC: oligodendrocyte progenitor cell.  
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 FTY720’s primary mode of action is immunomodulation by the regulation of T 
lymphocyte trafficking. FTY720 sequesters activated T lymphocytes in the lymph nodes, which 
is important in MS because it restricts these lymphocytes from migrating to inflammation sites, 
thereby preventing the harmful demyelination that is associated with MS. FTY720 also exerts 
direct effects on the CNS, including effects on astrocytes and oligodendrocyte progenitor cells 
(OPCs); however, the therapeutic benefit of these effects in MS is less clear. This investigation 
used a qualitative systems biology approach, aided by the computer modeling tool, CellDesigner, 
to explore the actions of S1P and FTY720P on the S1P receptors.  
 
4. Systems Biology and CellDesigner 
 Systems biology is the comprehensive study of interacting networks of genes, proteins, 
and biochemical reactions as part of a system (ISB, 2008). A systems biology approach requires 
large amounts of biological data, making the use of a computer essential to track all parts of a 
system. Computer, or in silico, experiments are inexpensive and fast whereas in vivo or in vitro 
lab experiments can be expensive and slow. Additionally, in silico experiments allow research to 
be done in areas where lab experiments are not feasible due to ethical or safety concerns.  
 In order to standardize systems biology research and allow for the integration of 
computational resources, Systems Biology Markup Language (SBML) and Systems Biology 
Workbench (SBW) were developed (Sauro et al., 2003). SBML is a machine-readable format for 
representing biochemical reaction networks (Funahashi et al., 2007). SBW is an open-source 
framework that enables heterogeneous software applications to communicate, allowing 
developers to form new applications in any programming language, while providing a simple 
user interface (SBW, 2006).  
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Many software packages are SBML compliant and support SBW. One of these programs, 
CellDesigner, was developed by Funahashi et al. in 2003 and is a modeling tool of gene-
regulatory and biochemical networks. CellDesigner also supports integration with SBML 
ordinary differential equation (ODE) Solver (SOSlib), allowing for simulation of models through 
a graphical user interface when kinetic rate laws and initial amounts of species are assigned. 
CellDesigner was the program used here for the modeling and simulation of the actions of S1P 
and FTY270P on the S1P receptors.  
 
5. Modeling Methods 
 Extensive literature surveys were used to identify species involved in S1P receptor-
mediated signaling and to determine the actions of S1P and FTY720P on the S1P receptors. 
These data were combined in CellDesigner to form five comprehensive models illustrating the 
actions of S1P and FTY720 on each of the five S1P receptors. The S1P receptor models were 
later combined to create cell type models (see Section 5.4).  
Species in the S1P receptor models were identified internally by CellDesigner using the 
notation “sn” where “n” is an integer. For example, in the S1P1 model, species were indentified 
“s1”, “s2”, etc. for all species involved. In the cell type models, which contained more than one 
S1P receptor type, “a”, “b”, “c”, “d”, or “e” was used instead of “s” to specify if S1P1, S1P2, 
S1P3, S1P4, or S1P5, respectively was signaling the species. For example, in the OPC model, 
which combined the models of S1P1, S1P3, and S1P5, the guanine nucleotide binding protein 
Ras, was activated by S1P1 and S1P3 signaling. Ras that was activated by S1P1 signaling was 
identified as “a21”, whereas Ras that was activated by S1P3 signaling was identified as “c19”. 
Next, kinetic rate laws and initial amounts of species were assigned for the S1P receptor models.   
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5.1 Kinetic Rate Laws  
Kinetic rate laws, including rate constants and kinetic orders, were assigned as described 
using the sample model seen in Figure 2. 
 
Figure 2. Sample CellDesigner model. 
 
The kinetic rate law for reaction 1 in the sample model in Figure 2 is: 
   re1  k  s1	  s2  s6   (1) 
where “k” is the rate constant for the reaction and “g1”, “g2”, and “g3” are kinetic orders, which 
describe the influence of the species on the reaction. Reaction 2 involves inhibition and is 
modeled with the kinetic rate law: 
   re2 


 k  s3	    (2) 
where “ki” is the inhibition rate constant, “k” is the rate constant, and “g1” is a kinetic order.  
 Dissociation constants (Kd) reported in the literature for the binding of the ligands, S1P 
and FTY720P, to the S1P receptors can be seen in Table 1. Kd is equal to 


 at equilibrium, 
where “kr” and “kf” are the reverse and forward rate constants, respectively, in the ligand (L)-
receptor (R) reversible reaction (Krohn and Link, 2003) shown in eq 3:  
                                              
R+L LR
kf
kr
 
             (3) 
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Therefore, kinetic rate laws for the binding of the ligands, S1P and FTY720P, to the S1P 
receptors were expressed in the form: 
   re  kf  R  L  kr  LR   (4) 
and were assigned “kf” and “kr” values based on the  reported Kd value given in the literature. 
For example, the Kd value of FTY720P for S1P1 was 0.3 nM; thus, “kr” was 0.3 and “kf” was 1. 
Kinetic orders were 1 and thus are not shown. Rate constants for other reactions in the models 
were assigned a base value of 1 and were adjusted if needed to more accurately reproduce results 
in the literature. Details regarding the assignment of rate constants are included in Tables 3–7. 
Kinetic orders of species that had a direct effect in a reaction were assigned a value of 1. 
For example, “s1” in the sample model in Figure 2 directly affects the production of “s3”, as it is 
depleted to create “s3”. Therefore the kinetic order of “s1” (labeled “g1”) is 1. In contrast, 
kinetic orders of species that had an indirect effect in a reaction were assigned a base value of 3 
and were adjusted if needed to more accurately reproduce results in the literature (see Tables 3–7 
for details). For example, “s6” in the sample model in Figure 2 indirectly affects the production 
of “s3” because it triggers reaction 1 without being depleted. Therefore, the kinetic order of “s6” 
(labeled “g3”) is 3. Increasing the kinetic order of a species would result in that species having a 
greater influence on the reaction, meaning that a greater amount of the species is necessary for 
the reaction to proceed. Likewise, decreasing the kinetic order of a species would mean that a 
smaller amount of the species is necessary for the reaction to proceed. The system of assigning 
kinetic orders was based on likely ranges as described in Torres and Voit (2002). 
5.2 Initial Amounts of Species  
In addition to assigning kinetic rate laws, initial amounts of species representing their 
presence in the models were assigned. These “presence” values did not have units of 
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concentration as they only indicated whether or not a species was present in the model and its 
relative presence compared to other species. Nonactivated species were assigned an initial 
amount of 1. Activated species, as indicated in the model with a subscript “a” and a second 
dashed line around the species (Figure 3), were assigned an initial amount of 0. In some of the 
cell type models, the initial amounts of the receptors were changed. For example, in the OPC 
model, S1P3 and its inactivated G proteins, Gi, Gq, and G12/13, were assigned initial amounts of 
0.5 to reflect the presence of fewer S1P3 receptors in OPCs compared with S1P1 or S1P5 
receptors.  
 
Figure 3. CellDesigner graphical notation (adapted from Kitano et al., 2005). 
 
5.3 Simulations in CellDesigner  
Once values were assigned for rate constants, kinetic orders, and initial amounts of 
species, the models were simulated using CellDesigner. The amount of each species in a model 
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throughout the simulation was calculated by solving a set of differential equations. In the sample 
model in Figure 2, “s3” is created by reaction 1 and depleted by reaction 2. Therefore, the rate of 
change in “s3” is:  
    


 re1  re2    (5) 
Similarly, the rate of change in “s1” is: 
 
	

 re1      (6) 
and the rate of change in “s5” is: 
    


 re2      (7) 
“s6” and “s7” do not change and are thus considered dependent variables, as they are not created 
or depleted in a reaction. CellDesigner uses SBML ODE Solver (SOSlib) to solve the set of 
ordinary differential equations in the system, thereby calculating the amounts of each species 
present throughout a simulation.  
5.4 Modeling Different Cell Types 
Different cell types were modeled by combining the S1P receptor models. For example, 
the model of an endothelial cell contained the models of S1P1 and S1P3. As previously 
mentioned, species in the cell type models were identified based on what S1P receptor was 
signaling the species. For example, in the OPC model, Ras that was activated by S1P1 signaling 
was identified as “a21”, whereas Ras that was activated by S1P3 signaling was identified as 
“c19”. Another set of identifiers was created to refer to the cumulative amounts of species in the 
model. For example, “t26” was assigned a value of “a21” + “c19” and therefore represented the 
total amount of Ras in the endothelial cell model. Separating the species in this way allowed for 
a better understanding of how each receptor and its associated signaling pathways affected the 
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cell type. The separation of species used in this method for modeling different cell types was 
supported by the assumption that there are spatial gradients of signaling molecules (Linderman, 
2009). Table 2 shows the cell types that were modeled in this project and their relative presence 
of S1P receptors. 
Table 2. Cell types modeled and their relative presence of S1P receptors. 
Cell type S1P receptors 
Lymphocyte S1P1 
Endothelial cell S1P1 = S1P3 
Astrocyte S1P1 = S1P3 
OPC S1P1 > S1P5 > S1P3 
 
 
6. Development of the S1P1, S1P2, S1P3, S1P4, and S1P5 Models 
 Each S1P receptor was modeled separately. These models can be seen in Figures 4–8 
with accompanying reactions in Tables 3–7. Figure 3 shows the graphical notations used by 
CellDesigner in the creation of the S1P receptor models.  
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Figure 4. CellDesigner model of S1P1. 
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Figure 5. CellDesigner model of S1P2.  
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Figure 6. CellDesigner model of S1P3.  
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Figure 7. CellDesigner model of S1P4.  
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Figure 8. CellDesigner model of S1P5.  
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Table 3. Reactions in S1P1 model. 
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re1 AC AC act. S1P1 Giα 

 	!	 "α
   k   AC; ki = 1 E-4, k = 0.3 
Inhibition, k = 0.3 to give time for 
S1P1 Giα to accumulate at 
initiation of simulation 
re2 S1P1 Giβγ, S1P1 Giα 
S1P1 Gi inact. 
 
k  S1P1 Giβγ  S1P1 Giα; k = 0 Reverse reaction 
re3 PLC act. PLC 
 
k   PLC act.; k = 0 Reverse reaction 
re4 IP3, DAG PIP2 
 
k   IP3   DAG; k = 0 Reverse reaction 
re5 Ca2+ act. Ca2+ 
 
k   Caact.; k = 0 Reverse reaction 
re6 Ras act. Ras 
 
k   Ras act.; k = 0 Reverse reaction 
re7 ERK act. ERK 
 
k   ERK act.; k = 0 Reverse reaction 
re8 PI3K act. PI3K 
 
k   P13K act.; k = 0 Reverse reaction 
re9 Akt act. Akt 
 
k   Akt act.; k = 0 Reverse reaction 
re10 Rac-GEF act. Rac-GEF 
 
k   Rac– GEF act.; k = 0 Reverse reaction 
re11 Rac act. Rac 
 
k   Rac act.; k = 0 Reverse reaction 
re12 cAMP ATP 
 
k   cAMP; k = 0 Reverse reaction 
re13 Empty S1P1, FTY720P S1P1⋅FTY720P  
kf   Empty S1P1   FTY720P –  kr   S1P1⋅FTY720P; kf = 1, 
kr = 0.3 Kd ≈ 0.3 nM (Table 1) 
re14 Akt Akt Act. PI3K act. k   Akt	  P13K act.; k = 1, g1 = 1, g2 = 3  
re15 Rac-GEF Rac-GEF act. Akt act. k   Rac– GEF	  Akt act.; k = 1, g1 = 1, g2 = 3  
re16 Rac, GTP Rac act., GDP Rac-GEF act. k   Rac	   Rac–GEF act.; k = 1, g1 = 1, g2 = 3  
re17 S1P1 Gi inact., GTP 
S1P1 Giβγ, S1P1 
Giα, GDP 
S1P1⋅S1P, 
S1P1⋅FTY720P 
k   S1P1 Gi inact.	  S1P1⋅S1P <  S1P1⋅FTY720P;  k = 1, g1 
= 1, g2 = 3, g3 = 3 
Reaction catalyzed by S1P1⋅S1P 
and S1P1⋅FTY720P  
re18 AC act. AC 
 
k   AC act.  S1P1 Giα; k = 0 Reverse reaction 
re19 Empty S1P1, S1P S1P1⋅S1P  kf   S1P   Empty S1P1 – kr   S1P1⋅S1P; kf = 1; kr = 13 Kd ≈ 13 nM (Table 1) 
re20 ATP cAMP AC act. k   ATP	   AC act.; k = 1, g1 = 1, g2 = 5 
g2 = 5 to require significant 
accumulation of AC act. before 
activating the conversion of ATP 
to cAMP 
re21 PIP2 IP3, DAG PLC act. k   PIP2	   PLC act.; k = 1, g1 = 1, g2 = 3  
(continued) 
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Table 3 continued. 
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re22 Ca2+ Ca2+ act. IP3 k   Ca=>  IP3; k = 1, g1 = 1, g2 = 3  
re23 PLC PLC act. S1P1 Giβγ k   PLC	  S1P1 Giβγ; k = 1, g1 = 1, g2 = 6 
g2 = 6 because high concentration 
of Giβγ subunits are required to 
activate PLC (Birnbaumer, 1992)  
re24 ERK ERK act. Ras act. k   ERK	   Ras act.; k = 1, g1 = 1, g2 = 3  
re25 Ras Ras act. S1P1 Giβγ k   Ras	  S1P1 Giβγ; k = 1, g1 = 1, g2 = 3  
re26 PI3K PI3K act. S1P1 Giβγ k   PI3K	  S1P1 Giβγ; k = 1, g1 = 1, g2 = 3  
re27 S1P1⋅FTY720P Degraded FTY720P  k  S1P1⋅FTY720P; k = 10 
k = 10 for rapid degradation; re27 
only included in lymphocyte 
model 
Reverse reactions were given a rate constant of 0 and thus had no role in the model. 
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Table 4. Reactions in S1P2 model.  
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re1 Empty S1P2, S1P S1P2⋅S1P  kf  Empty S1P2   S1P   kr  S1P2⋅S1P; kf = 1, kr = 25 Kd ≈ 25 nM (Table 1) 
re2 S1P2 Gi inact., GTP 
S1P2 Giβγ, S1P2 
Giα, GDP 
S1P2⋅S1P k   S1P2 Gi inact.	 S1P2⋅S1P;  k = 1, g1 = 1, g2 = 5 
g2 = 5 because coupling to Gi 
appears to be less efficient than 
coupling in to Gi in S1P1 and 
S1P3 (Sugimoto et al., 2003) 
re3 S1P2 Gq inact., GTP 
S1P2 Gqβγ, S1P2 
Gqα, GDP S1P2⋅S1P k   S1P2 Gq inact.
	 S1P2⋅S1P; k = 1, g1 = 1, g2 = 3  
 
re4 S1P2 G12/13 inact., GTP 
S1P2 G12/13βγ, 
S1P2 G12/13α, 
GDP 
S1P2⋅S1P k   S1P2 G12/13 inact.	 S1P2⋅S1P; k = 1, g1= 1, g2 = 2 
g2 = 2 because S1P2 couples most 
strongly to G12/13 (Taha et al., 
2004) 
re5 PI3K PI3K act. S1P2 Giβγ k  PI3K	  S1P2 Giβγ; k = 1, g1= 1, g2 = 3 
 
re6 Rac-GEF Rac-GEF act. PI3K act. k  Rac– GEF	  PI3K act.; k = 1, g1 = 1, g2 = 3 
 
re7 ERK ERK act.  Ras act. k  ERK	  Ras act.; k = 1, g1 = 1, g2 = 4 
g2 = 4 because S1P2 is a less 
powerful activator of ERK than 
S1P1 and S1P3 (Taha et al., 2004) 
re8 Ras Ras act. S1P2 Giβγ k   Ras	   S1P2 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re9 AC AC act.  S1P2⋅S1P k  AC	  S1P2⋅S1P; k = 1, g1 = 1, g2 = 3 Unknown mechanism 
re10 JNK JNK act.  S1P2⋅S1P k  JNK	  S1P2⋅S1P; k = 1, g1 = 1, g2 = 3 Unknown mechanism 
re11 p38 p38 act.  S1P2⋅S1P k  p38	  S1P2⋅S1P; k = 1, g1 = 1, g2 = 3 Unknown mechanism 
re12 iPLC iPLC act. S1P2 Giβγ k  iPLC	  S1P2 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re13 iPIP2 iIP3, iDAG iPLC act. k  iPIP2	  iPLC act.; k = 1, g1 = 1, g2 = 3 
 
re14 iCa2+ iCa2+ act. iIP3 k  iCa
	   iIP3; k = 1, g1 = 1, g2 = 3 
 
 
re15 qPLC qPLC act. S1P2 Gqα k  qPLC	  S1P2 Gqα; k = 1, g1 = 1, g2 = 3 
 
re16 Rac-GAP Rac-GAP act. Rho act.  k  Rac– GAP	  Rho act.; k = 1, g1 = 1, g2 = 3 
 
re17 Rho, GTP Rho act., GDP Rho-GEF act.  k  Rho	   Rho–GEF act.; k = 1, g1 = 1, g2 = 3 
 
re18 Rho-GEF Rho-GEF act.  S1P2 G12/13α k  Rho–GEF	   S1P2 G12/13α; k = 1, g1 = 1, g2 = 3 
 
re19 ATP cAMP AC act.  k   ATP	  AC act.; k = 1, g1 = 1, g2 = 3 
 
re20 Rac act. Rac 
 
k   Rac act.; k = 0 Reverse reaction 
(continued) 
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Table 4 continued. 
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re21 S1P2 Giα, S1P2 Giβγ 
S1P2 Gi inact. 
 
k   S1P1 Giα   S1P2 Giβγ; k = 0 Reverse reaction 
re22 iIP3, iDAG iPIP2 
 
k   iIP3   iDAG; k = 0 Reverse reaction 
re23 iCa2+ act. iCa2+ 
 
k   iCa act.; k = 0 Reverse reaction 
re24 S1P2 Gqα, S1P2 Gqβγ 
S1P2 Gq inact. 
 
k   S1P2 Gqα   S1P2 Gqβγ; k = 0 Reverse reaction 
re25 qPLC act. qPLC 
 
k   qPLC act.; k = 0 Reverse reaction 
re26 ERK act.  ERK 
 
k   ERK act. ; k = 0 Reverse reaction 
re27 Ras act. Ras 
 
k   Ras act.; k = 0 Reverse reaction 
re28 PI3K act. PI3K 
 
k   PI3K act.; k = 0 Reverse reaction 
re29 Rac-GEF act. Rac-GEF 
 
k   Rac–GEF act.; k = 0 Reverse reaction 
re30 AC act.  AC 
 
k   AC act.; k = 0 Reverse reaction 
re31 cAMP ATP 
 
k   cAMP; k = 0 Reverse reaction 
re32 JNK act.  JNK 
 
k   JNK act.; k = 0 Reverse reaction 
re33 p38 act.  p38 
 
k   p38 act.; k = 0 Reverse reaction 
re34 S1P2 G12/13α, S1P2 G12/13βγ 
S1P2 G12/13 inact. 
 
k   S1P2 G12/13α   S1P2 G12/13βγ; k = 0 Reverse reaction 
re35 Rho-GEF act.  Rho-GEF 
 
k   Rho–GEF act.; k = 0 Reverse reaction 
re36 Rho act.  Rho 
 
k   Rho act.; k = 0 Reverse reaction 
re37 Rac-GAP act. Rac-GAP 
 
k   Rac–GAP act.; k = 0 Reverse reaction 
re38 Rac, GTP Rac act., GDP Rac-GEF act., Rac-GAP act. 

 FGHI"J! GH.
   k   Rac	Rac–GEF act.; ki = 1 E-4, k = 1, g1 = 
1, g2 = 3 
Inhibition 
re39 iPLC act. iPLC 
 
k   qPLC act.; k = 0 Reverse reaction 
re40 qPIP2 qIP3, qDAG qPLC act. k   qPIP2	  qPLC act.; k = 1, g1 = 1, g2 = 3 
 
re41 qIP3, qDAG qPIP2 
 
k   qIP3   qDAG; k = 0 Reverse reaction 
re42 qCa2+ qCa2+ act. qIP3 k  qCa	   qIP3; k = 1, g1 = 1, g2 = 3 
 
re43 qCa2+ act. qCa2+ 
 
k   qCa act.; k = 0 Reverse reaction 
Reverse reactions were given a rate constant of 0 and thus had no role in the model. 
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Table 5. Reactions in S1P3 model. 
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re1 S1P3 Gi inact., GTP 
S1P3 Giβγ, S1P3 
Giα, GDP 
S1P3⋅S1P, 
S1P3⋅FTY720P 
k   S1P3 Gi inact.	   S1P3⋅S1P  < S1P3⋅FTY720P; k = 
1, g1 = 1, g2 = 3, g3 = 3 
 
Reaction catalyzed by S1P3⋅S1P 
and S1P3⋅FTY720P  
re2 ATP cAMP AC act. k  ATP	   AC act. ; k = 1, g1 = 1, g2 = 3 
 
re3 iPIP2 iDAG, iIP3 iPLC act. k   iPIP2	   iPLC act.; k = 1, g1 = 1, g2 = 3 
 
re4 Ca2+ Ca2+ act. iIP3 k   iCa	  iIP3; k = 1, g1 = 1, g2 = 3 
 
re5 ERK ERK act. Ras act. k   ERK	   Ras act.; k = 1, g1 = 1, g2 = 3 
 
re6 iPLC iPLC act. S1P3 Giβγ k   iPLC	   S1P3 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re7 PI3K PI3K act. S1P3 Giβγ k   PI3K	  S1P3 Giβγ; k = 1, g1 = 1, g2 = 2 
g2 = 2 because S1P3 couples 
most strongly to Gi (Taha et al., 
2004) 
re8 Rac-GEF Rac-GEF act. PI3K act. k   Rac–GEF	  PI3K act.; k = 1, g1 = 1, g2 = 3 
 
re9 Ras Ras act. S1P3 Giβγ k   Ras	   S1P3 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re10 iPLC iPLC act. S1P3 Gqα k   iPLC	  S1P3 Gqα; k = 1, g1 = 1, g2 = 3 
 
re11 S1P3 G12/13 inact., GTP 
S1P3 G12/13βγ, 
S1P3 G12/13α, 
GDP 
S1P3⋅S1P k   S1P3 G12/13 inact.	 S1P3⋅S1P; k = 1, g1 = 1, g2 = 3 
 
re12 Rho-GEF Rho-GEF act. S1P3 G12/13α k  Rho  GEF	  S1P3 G12/13α; k = 1, g1 = 1, g2 = 3 
 
re13 Rho, GTP Rho act., GDP Rho-GEF act. k   Rho	  Rho–GEF act.; k = 1, g1 = 1, g2 = 3 
 
re14 Rac-GAP Rac-GAP act. Rho act. k   Rac– GAP	   Rho act.; k = 1, g1 = 1, g2 = 3 
 
re15 Empty S1P3, S1P S1P3⋅S1P  kf  Empty S1P3  S1P   kr  S1P3⋅S1P; kf = 1, kr = 25 Kd ≈ 25 nM (Table 1) 
re16 Empty S1P3, FTY720P S1P3⋅FTY720P  kf  Empty S1P3  FTY720P   kr  S1P3⋅FTY720P; kf = 1, kr = 3.1 Kd ≈ 3.1 nM (Table 1) 
re17 Rac act. Rac 
 
k  Rac act.; k = 0 Reverse reaction 
re18 AC act. AC 
 
k  AC act.; k = 0 Reverse reaction 
re19 Rho act. Rho 
 
k   Rho act.; k = 0 Reverse reaction 
re20 S1P3 Giα, S1P3 Giβγ 
S1P3 Gi inact. 
 
k   S1P3 Giα  S1P3 Giβγ; k = 0 Reverse reaction 
(continued) 
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Table 5 continued.  
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re21 iIP3, iDAG iPIP2 
 
k   iIP3   iDAG;  k = 0 Reverse reaction 
re22 iCa2+ act. iCa2+ 
 
k   iCa2 <  act.; k = 0 Reverse reaction 
re23 iPLC act. iPLC 
 
k   iPLC act.; k = 0 Reverse reaction 
re24 PI3K act. PI3K 
 
k   PI3K act.; k = 0 Reverse reaction 
re25 Rac-GEF act. Rac-GEF 
 
k   Rac  GEF act.; k = 0 Reverse reaction 
re26 iPLC act. iPLC 
 
k   iPLC act.; k = 0 Reverse reaction 
re27 S1P3 Gqβγ, S1P3 Gqα 
S1P3 Gq inact. 
 
k   S1P3 Gqβγ   S1P3 Gqα; k = 0 Reverse reaction 
re28 S1P3 G12/13βγ, S1P3 G12/13α 
S1P3 G12/13 inact. 
 
k   S1P3 G12/13βγ   S1P3 G12/13α; k = 0 Reverse reaction 
re29 Rho-GEF act. Rho-GEF 
 
k   Rho–GEF act.; k = 0 Reverse reaction 
re30 Ras act. Ras 
 
k   Ras act.; k = 0 Reverse reaction 
re31 ERK act. ERK 
 
k   ERK act.; k = 0 Reverse reaction 
re32 cAMP ATP 
 
k   cAMP; k = 0 Reverse reaction 
re33 Rac-GAP act. Rac-GAP 
 
k   Rac–GAP act.; k = 0 Reverse reaction 
re34 AC AC act. S1P3 Giα 

   	! "α
  k   AC	; ki = 0.001, k = 1, g1 = 1 Inhibition 
re35 Rac, GTP Rac act., GDP Rac-GEF act., Rac-GAP act. 

  FGHI"J! GH.
  k  Rac	  Rac– GEF act. ; ki = 01; k = 1, g1 = 1, 
g2 = 3 
Inhibition 
re36 S1P3 Gq inact., GTP 
S1P3 Gqβγ, S1P3 
Gqα, GDP 
S1P3⋅S1P, 
S1P3⋅FTY720P 

   	!⋅LMNO!
 k   S1P3 Gq inact.	  S1P3⋅S1P; ki = 1E-4, k = 
1, g1 = 1, g2 = 3 
Inhibition 
re38 qPIP2 qDAG, qIP3 qPLC act. k   qPIP2	  qPLC act; k = 1, g1 = 1, g2 = 3 
 
re39 qCa2+ qCa2+ act. qIP3 k   qCa	  qIP3; k = 1, g1 = 1, g2 = 3 
 
re40 qIP3, qDAG qPIP2 
 
k   qIP3   qDAG; k = 0 Reverse reaction 
re41 qCa2+ act. qCa2+ 
 
k   qCa act.; k = 0 Reverse reaction 
Reverse reactions were given a rate constant of 0 and thus had no role in the model. 
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Table 6. Reactions in S1P4 model.  
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re1 Empty S1P4, S1P S1P4⋅S1P  kf  Empty S1P4   S1P   kr  S1P4⋅S1P; kf = 1, kr = 15 Kd ≈ 15 nM (Table 1) 
re2 Empty S1P4, FTY720P S1P4⋅FTY720P  
kf  Empty S1P4   FTY720P   kr  S1P4⋅FTY720P; kf = 1, 
kr = 0.6 
 
Kd ≈ 0.6 nM (Table 1) 
re3 S1P4 Gi inact., GTP 
S1P4 Giβγ, S1P4 
Giα, GDP 
S1P4⋅S1P, 
S1P4⋅FTY720P 
k   S1P4 Gi inact.	  S1P4⋅S1P < S1P4⋅FTY720P; 
k = 1, g1 = 1, g2 = 3, g3 = 3 
Reaction catalyzed by 
S1P4⋅S1P and S1P4⋅FTY720P  
re4 Ca2+ Ca2+ act. IP3 k   Ca=>   IP3; k = 1, g1 = 1, g2 = 3 
 
re5 ATP cAMP AC act. k   ATP	  AC act.; k = 1, g1 = 1, g2 = 3 
 
re6 S1P4 G12/13 inact., GTP 
S1P4 G12/13βγ, S1P4 
G12/13α, GDP 
S1P4⋅S1P, 
S1P4⋅FTY720P 
k   S1P4 G12/13 inact.	   S1P4⋅S1P <
S1P4⋅FTY720P; k = 1, g1 = 1, g2 = 3, g3 = 3 
Reaction catalyzed by 
S1P4⋅S1P and S1P4⋅FTY720P  
re7 PLC PLC act. S1P4 Giβγ k   PLC	  S1P4 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re8 PIP2 DAG, IP3 PLC act. k   PIP2	  PLC act.; k = 1, g1 = 1, g2 = 3 
 
re9 AC AC act. S1P4⋅S1P, S1P4⋅FTY720P 
k   AC	  S1P4⋅S1P < S1P4⋅FTY720P; k = 1, g1 = 
1, g2 = 3, g3 = 3 
Unknown mechanism; reaction 
catalyzed by S1P4⋅S1P and 
S1P4⋅FTY720P  
re10 ERK ERK act. Ras act. k   ERK	   Ras act.; k = 1, g1 = 1, g2 = 3 
 
re11 Cdc42 Cdc42 act. S1P4⋅S1P, S1P4⋅FTY720P 
k   Cdc42	  S1P4⋅S1P < S1P4⋅FTY720P; k = 1, 
g1 = 1, g2 = 3, g3 = 3 
Unknown mechanism; reaction 
catalyzed by S1P4⋅S1P and 
S1P4⋅FTY720P  
re12 Ras Ras act. S1P4 Giβγ k   Ras	   S1P4 Giβγ; k = 1, g1 = 1, g2 = 3 
 
re13 Rho-GEF Rho-GEF act. S1P4 G12/13α k   Rho–GEF	   S1P4 G12/13α; k = 1, g1 = 1, g2 = 3 
 
re14 Rho, GTP Rho act., GDP Rho-GEF act. k  Rho	  Rho–GEF act.; k = 1, g1 = 1, g2 = 3 
 
re15 S1P4 Giβγ, S1P4 Giα 
S1P4 Gi inact. 
 
k    S1P4 Giβγ  S1P4 Giα; k = 0 Reverse reaction 
re16 S1P4 G12/13βγ, S1P4 G12/13α 
S1P4 G12/13 inac. 
 
k   S1P4 G12/13βγ  S1P4 G12/13α; k = 0 Reverse reaction 
re17 Ca2+ act. Ca2+ 
 
k   Ca act. ; k = 0 Reverse reaction 
re18 IP3, DAG PIP2 
 
k   IP3   DAG; k = 0 Reverse reaction 
(continued) 
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Table 6 continued.  
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re19 PLC act. PLC 
 
k   PLC act. ; k = 0 Reverse reaction 
re20 Rho act. Rho 
 
k   Rho act. ; k = 0 Reverse reaction 
re21 Rho-GEF act. Rho-GEF  
 
k   Rho–GEF act. ; k = 0 Reverse reaction 
re22 AC act. AC 
 
k   AC act. ; k = 0 Reverse reaction 
re23 cAMP ATP 
 
k   cAMP; k = 0 Reverse reaction 
re24 Ras act. Ras 
 
k   Ras act. ; k = 0 Reverse reaction 
re25 ERK act. ERK 
 
k   ERK act. ; k = 0 Reverse reaction 
re26 Cdc42 act. Cdc42 
 
k   Cdc42 act. ; k = 0 Reverse reaction 
Reverse reactions were given a rate constant of 0 and thus had no role in the model. 
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Table 7. Reactions in S1P5 model. 
ID Reactants Products Modifiers Kinetic rate laws; parameter assignments Notes 
re1 Empty S1P5, FTY720P S1P5⋅FTY720P   kf  Empty S1P5  FTY720P  kr  S1P5⋅FTY720P; kf = 1, kr = 0.3 Kd ≈ 0.3 nM (Table 1)  
re2 Empty S1P5, S1P S1P5⋅S1P   kf  Empty S1P5  S1P  kr  S1P5⋅S1P; kf = 1, kr = 2 Kd ≈ 2 nM (Table 1)   
re3 S1P5 Gi inact., GTP 
S1P5 Giβγ, S1P5 
Giα, GDP 
S1P5⋅S1P, 
S1P5⋅FTY720P 
k  S1P5 Gi inact.	 S1P5⋅S1P < S1P5⋅FTY720P; k = 1, 
g1 = 1, g2 = 3, g3 = 3 
 Reaction catalyzed by S1P5⋅S1P 
and S1P5⋅FTY720P 
re4 ATP cAMP AC act. k  ATP	AC act.; k = 1, g1 = 1, g2 = 3   
re5 S1P5 G12/13 inact., GTP 
S1P5 G12/13βγ, 
S1P5 G12/13α, 
GDP 
S1P5⋅S1P, 
S1P5⋅FTY720P 
k   S1P5 G12/13 inact.	   S1P5⋅S1P < S1P5⋅FTY720P; 
k = 1, g1 = 1, g2 = 3, g3 = 3 
Reaction catalyzed by S1P5⋅S1P 
and S1P5⋅FTY720P  
re6 AC act. AC   k   AC act.; k = 0 Reverse reaction 
re7 ERK act. ERK   k   ERK act.; k = 0 Reverse reaction 
re8 JNK act. JNK   k   JNK act.; k = 0 Reverse reaction 
re9 S1P5 G12/13βγ, S1P5 G12/13α 
S1P5 G12/13 inact.   k   S1P5 G12/13βγ   S1P5 G12/13α; k = 0 Reverse reaction 
re10 S1P5 Giβγ, S1P5 Giα 
S1P5 Gi inact.   k   S1P5 Giβγ   S1P5 Giα; k = 0 Reverse reaction 
re11 cAMP ATP   k   cAMP; k = 0 Reverse reaction 
re12 AC AC act. S1P5 Giα 

   	! "α
 k  AC	; ki = 0.001, k = 1, g1 = 1 Inhibition 
re13 ERK  ERK act. S1P5⋅S1P, S1P5⋅FTY720P 

   	!⋅ 	!
  
 
   	!⋅LMNO
   k   ERK	; ki = 0.001, k = 1, g1 = 1 Inhibition; reaction inhibited by S1P5⋅S1P and S1P5⋅FTY720P 
re14 JNK  JNK act. S1P5⋅S1P, S1P5⋅FTY720P 
k  JNK	  S1P5⋅S1P < S1P5⋅FTY720P; k = 1, g1 = 1, g2 
= 3, g3 = 3 
 Reaction catalyzed by S1P5⋅S1P 
and S1P5⋅FTY720P 
re15 Rho, GTP Rho act., GDP Rho-GEF act. k   Rho	  Rho–GEF act.; k = 1, g1 = 1, g2 = 3   
re16 Rho-GEF Rho-GEF act. S1P5 G12/13α k  Rho–GEF	  S1P5 G12/13α; k = 1, g1 = 1, g2 = 3   
re17 Rho-GEF act. Rho-GEF   k  Rho–GEF act. ; k = 0 Reverse reaction 
re18 Rho act. Rho   k   Rho act.; k = 0 Reverse reaction 
Reverse reactions were given a rate constant of 0 and thus had no role in the model. 
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6.1 S1P1  
 S1P1 couples to the heterotrimeric G protein Gi (Windh et al. 1999). In most cell types, 
S1P and FTY720P act on S1P1 through the Giα subunit of S1P1/Gi to inhibit the membrane-
bound effector enzyme, adenylate cyclase (AC) (Okamoto et al., 1998). When not inhibited, AC 
converts ATP to the diffusible second messenger, cyclic AMP (cAMP). cAMP can activate a 
cAMP-dependent protein kinase, protein kinase A (PKA), which phosphorylates target proteins 
(not modeled). 
S1P and FTY720P signaling through the Giβγ subunit of S1P1/Gi activates the small 
monomeric G protein Ras, phospholipase C (PLC), and phosphoinositide 3-kinase β (PI3Kβ) 
(reviewed in Sanchez and Hla, 2004). Ras activates extracellular signal-related kinase (ERK), 
which is involved in cell proliferation and survival. PLC catalyzes the generation of inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) from phosphatidyl inositol 4,5-bisphosphate 
(PIP2). DAG is a lipophilic second messenger that is associated with the plasma membrane. IP3 
diffuses through the cytosol and interacts with IP3-gated channels on the membrane of the 
endoplasmic reticulum (ER), causing the release of calcium into the cytosol.  
PI3Kβ, which is also activated by signaling through the Giβγ subunit of S1P1/Gi, 
activates Akt, also known as protein kinase B. Akt binds to S1P1 and phosphorylates the third 
intracellular loop at the Thr236 residue. This phosphorylation (which is modeled but not explicitly 
illustrated) is required for activation of the small GTPase Rac, cortical actin assembly, and cell 
migration (Lee et al., 2001).  
 After antigen exposure in the lymph nodes, native T lymphocytes become activated and 
down-regulate S1P1. Following the proliferation phase, the activated T lymphocytes up-regulate 
S1P1 and egress from the lymph nodes in response to an S1P gradient between the blood and the 
30 
lymph nodes (Brinkmann et al., 2004). FTY720P causes the internalization and degradation of 
S1P1 (Matloubian et al., 2004), significantly reducing S1P- or FTY720P-mediated signaling. 
6.2 S1P2 
S1P2 couples to the heterotrimeric G proteins, Gi, Gq, and G12/13 (Windh et al., 1999). 
S1P acts on S1P2 through the Giβγ subunit of S1P2/Gi to activate Ras, PLC, and PI3Kβ. As in 
S1P1 signaling, Ras activates ERK, and PLC catalyzes the generation of IP3 and DAG from 
PIP2. IP3 interacts with IP3-gated channels on the membrane of the ER, causing the release of 
calcium into the cytoplasm. PI3Kβ activates Rac, which is involved in cortical actin assembly 
and cell migration.  
S1P acts on S1P2 through the Gqα subunit of S1P2/Gq to activate PLC, which catalyzes 
the same signaling events described in association with Gi-mediated activation of PLC. S1P also 
activates the small GTPase Rho via the activation of Rho-GDP/GTP exchange factor (Rho-GEF) 
by S1P2/G12/13α. Rho mediates stress fiber formation and focal adhesion (Hall, 1998). Rho 
activates the Rac-GTPase-activating protein (Rac-GAP), which strongly inhibits the activity of 
Rac. S1P2 couples more strongly to G12/13 than to Gi, resulting in the activation of Rho as the 
predominant pathway regulating Rac activity (Taha et al., 2004). As a result, signaling via S1P2 
inhibits cell migration and cortical actin assembly. Finally, S1P2 signaling activates AC and the 
mitogen-activated protein (MAP) kinases, JNK and p38 in an unknown mechanism (Kon et al., 
1999; Gonda et al., 1999).   
6.3 S1P3 
S1P3 couples to the heterotrimeric G proteins, Gi, Gq, and G12/13 (Windh et al., 1999). 
While S1P can activate Gi, Gq, and G12/13 signaling, FTY720P selectively activates the Gi protein 
of S1P3 (Sensken, 2008). In fact, FTY720P antagonizes S1P-induced activation of S1P3/Gq 
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signaling. This observation is an example of agonist-receptor trafficking, the idea that GPCRs 
can have more than one G protein-activating conformation and that each agonist can have a 
unique activation state (Perez and Karnik, 2005). It is unclear if FTY720P also antagonizes S1P-
induced activation of S1P3/G12/13 signaling, and therefore FTY720P was not modeled to 
antagonize or activate signaling through G12/13.  
S1P and FTY720P act on S1P3 through the Giα subunit of S1P3/Gi to inhibit AC. S1P 
and FTY720P also act on S1P3 through the Giβγ subunit of S1P3/Gi to activate Ras, PLC, and 
PI3Kβ (Kluk and Hla, 2002). As in S1P1 and S1P2 signaling, Ras activates ERK and PLC 
catalyzes the generation of IP3 and DAG from PIP2 (reviewed in Sanchez and Hla, 2004). IP3 
interacts with IP3-gated channels on the membrane of the ER, causing the release of calcium into 
the cytosol. As in S1P1 and S1P2 signaling, PI3Kβ activates Rac.  
S1P acts on S1P3 through the Gqα subunit of S1P3/Gq to activate PLC (Okamoto et al., 
1999), which catalyzes the same sequence of events as described in association with Gi 
activation of PLC. S1P also activates Rho via the activation of Rho-GEF by S1P3/G12/13α. Rho 
acts in opposition to Rac, promoting the formation of stress fibers and disrupting adherens 
junctions (Brinkmann et al., 2004). Rho activates Rac-GAP, which inhibits the activity of Rac. 
However, S1P3 promotes migration, suggesting that S1P3 couples more strongly to Gi than to 
G12/13, thereby primarily regulating cell migration through the activation of Rac (Taha et al., 
2004).   
6.4 S1P4 
S1P4 couples to the heterotrimeric G proteins, Gi and G12/13 (Yamazaki et al., 2000; Van 
Brocklyn et al., 2000). It is unclear if S1P and FTY720P activate the same signaling events in 
S1P4 signaling, as little research has been done on the actions of FTY720P on S1P4. For the 
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purpose of the model, it was assumed that FTY720P and S1P activate the same signaling events, 
as FTY720P is a potent ligand for S1P4 (Table 1). 
S1P and FTY720P act on S1P4 through the Giβγ subunit of S1P4/Gi to activate Ras and 
PLC. As in S1P1, S1P2, and S1P3 signaling, Ras activates ERK, and PLC catalyzes the 
generation of IP3 and DAG from PIP2 (Van Brocklyn et al., 2000; Yamazaki et al., 2000). IP3 
interacts with IP3-gated channels on the membrane of the ER, causing the release of calcium into 
the cytosol.  
S1P and FTY720P also activate Rho via the activation of Rho-GEF by S1P4/G12/13α 
(Gräler et al., 2003). S1P promotes cell migration in cells expressing S1P4. These actions are 
mediated by the activation of Cdc42, a member of the Rho family of small GTPases, in an 
unknown mechanism (Allen et al., 1998; Kohno et al., 2003). It was assumed that FTY720P also 
activates Cdc42 via S1P4 signaling. Finally, S1P4 signaling activates AC in an unknown 
mechanism (Ishii et al., 2001 as cited by Taha et al., 2004).  
6.5 S1P5 
S1P5 couples to the heterotrimeric G-proteins, Gi and G12/13 (Im et al., 2000). S1P and 
FTY720P act on S1P5 through the Giα subunit of S1P5/Gi to inhibit AC (Im et al., 2000; Malek 
et al., 2001; as cited by Sanchez and Hla, 2004). S1P and FTY720P also activate Rho via the 
activation of Rho-GEF by S1P5/G12/13α. Finally, S1P5 signaling activates JNK and inhibits ERK 
in an unknown mechanism (Malek et al., 2001 as cited by Sanchez and Hla, 2004). 
 
7. Discussion of Modeling Methods 
“All models are wrong, but some are useful” (Box and Draper, 1987). Indeed, models 
cannot be perfect and are by no means completely accurate representations of in vivo systems.  
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Nonetheless, the goal of most models, including the S1P receptor and cell type models created 
here, is to help recognize general patterns by integrating collections of observations into a higher 
level of biological organization (Voit, 2000). While the S1P receptor and cell type models 
discussed here were able to qualitatively reproduce results from the literature, there were several 
challenges faced when creating the models. These challenges are discussed below.  
7.1 Modeling Signal Transduction   
 Signal transduction cascades, as modeled in the S1P receptor and cell type models, do not 
involve the direct conversion of a reactant into a product as in a traditional chemical reaction 
such as S T B. Rather, signal transduction cascades involve an input that triggers a reaction, 
leading to production of a species. This species activates another reaction, leading to the 
production of another species. This pattern continues until a final product has been reached. The 
species that catalyze the reactions are acting indirectly, by signaling the next reaction, and they 
are not depleted in doing so. The presence of a catalyst signals the reaction to occur and 
influences what rate the reaction occurs at; it does not influence the total amount of product 
made. Therefore, the amount of each species activated at each step in the signal transduction 
cascade depends on how much of the reactant (in many cases, the nonactivated form of the 
species) was present.  
 Due to the nature of signal transduction cascades, the S1P receptors and cell types 
modeled here could not be analyzed quantitatively by looking at the amount of each activated 
species that was created. Instead, the relative presence of activated species and the relative 
kinetics of different reactions were determined upon treatment with S1P, FTY720P, or both 
compounds. 
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7.2 Modeling Termination of the Signal Transduction Pathway 
 Termination of the signal transduction pathway is initiated when Gα hydrolyzes the 
bound GTP to GDP by its intrinsic GTPase activity, allowing Gα to reassemble with Gβγ to form 
the inactive trimeric G protein (Lodish, 2007). Effector proteins are deactivated separately, by 
intrinsic enzymatic activity. While visual models of the S1P receptors and cell types included 
reverse reaction arrows to illustrate signal transduction termination, the rate constants for reverse 
reactions were assigned a value of 0, meaning that these reactions were not active in the 
simulations. Modeling the termination of the signal transduction pathway would have required 
the creation of an event to allow for the reassembly of Gα with Gβγ. However, this would not 
have prevented the rest of the signaling pathway from occurring to completion. In order for all 
species to return to their original amounts, numerous events would be needed to initiate all 
reverse reactions involved in the model. These reverse reactions were not necessary to illustrate 
the actions of S1P and FTY720P on the S1P receptors and therefore were not included in the 
models. However, they remain in the models (with rate constants of 0) to allow for convenient 
addition of rate constants should the reverse reactions be implemented in the future.  
 
8. Results 
 Four cell types were modeled: T lymphocytes, endothelial cells, astrocytes, and OPCs. 
For each cell type, relevant literature was addressed and simulations in CellDesigner were shown 
to demonstrate the model’s ability to qualitatively reproduce the results described in the 
literature.  
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8.1 T Lymphocytes and Endothelial Cells  
8.1.1 Regulation of T Lymphocyte Trafficking 
FTY720P’s primary mode of action is regulation of T lymphocyte trafficking via S1P1, 
which is present on both T lymphocytes and endothelial cells (Horga and Montalban, 2008). This 
mode of action is important in MS because activated T lymphocytes cross the BBB and trigger 
events that result in myelin, ODC, and axonal injury (Compston and Coles, 2002). FTY720P 
regulates T lymphocyte trafficking by inhibiting T lymphocyte egress from the lymph nodes by 
two independent mechanisms: internalization of S1P1 on T lymphocytes and enhanced 
endothelial barrier function.  
8.1.1.1 Internalization of S1P1 on T Lymphocytes 
 During normal immune system function, naïve T lymphocytes circulate between the 
blood and lymphatic tissue in search of foreign antigen (Brinkmann et al., 2004). T lymphocytes 
are activated upon finding an antigen. An activated T lymphocyte signals the down-regulation of 
S1P1 and as a result, T lymphocytes are unable to respond to an egress signal by S1P and the T 
lymphocytes remain trapped in the lymph nodes, where they proliferate (Matloubian et al., 
2004). Once the desired proliferation has been reached, activated T lymphocytes up-regulate 
S1P1 and respond to S1P to exit the lymph nodes to fight infection 
FTY720P induces aberrant internalization and degradation of S1P1, antagonizing S1P-
mediated signaling via S1P1 and rendering lymphocytes unable to respond to an egress signal 
provided by S1P (Matloubian et al., 2004). Treatment with pertussis toxin (PTX), which 
inactivates Gi, had no effect on the down-regulation of S1P1 mediated by FTY720P, indicating 
that Gi is not involved in the down-regulation of S1P1 (Sensken et al., 2008). It is unclear how 
FTY720P signals S1P1 for degradation.  
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8.1.1.2 Enhanced Endothelial Barrier Function  
Endothelial cells line the interior surface of blood vessels in the circulatory system. These 
cells are involved in regulating the permeability to proteins and cells through adherens junctions, 
and are relevant in T lymphocyte trafficking due to their role in regulating the permeability of 
lymphoid tissues (Kihara and Igarashi, 2008). The second mechanism by which FTY720P 
contributes to the regulation of lymphocyte trafficking is by mimicking the actions of S1P on 
S1P1, and to a lesser extent, on S1P3. S1P1 and S1P3 are present on sinus-lining endothelial 
cells within the lymph nodes. Unlike S1P1 receptors on lymphocytes, S1P1 receptors on 
endothelial cells are not down-regulated in response to FTY720P. Instead, FTY720P acts on 
S1P1/Gi and S1P3/Gi to activate Rac, which induces the translocation of vascular endothelial 
cadherin and β-catenin to the focal contact sites between endothelial cells, promoting adherens 
junction assembly (Figure 9). Additionally, the α-, β-, and γ-catenins anchor to the intracellular 
cortical actin ring of the cytoskeleton to stabilize the endothelium and enhance barrier function 
(Brinkmann et al., 2004), further restricting T lymphocyte egress.  
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Figure 9. Enhanced endothelial barrier function by FTY720P (Reprinted from Brinkmann et al., 2004). FTY720P 
promotes adherens junction assembly by inducing translocation of vascular endothelial cadherin and β-catenin to the 
focal contact sites between endothelial cells. The α-, β-, and γ-catenins connect to the intracellular cortical actin ring 
of the cytoskeleton to enhance endothelial barrier function.   
 
FTY720P acts similarly on brain endothelial cells to promote adherens junction 
assembly, thereby decreasing the permeability of the BBB (Miron et al., 2008). Indeed, Foster et 
al. (2008) found that late-stage treatment with FTY720 of Dark Agouti rats with experimental 
autoimmune encephalomyelitis (EAE), the animal model of MS, resulted in a reversal of BBB 
leakage. In MS, increased permeability of the BBB allows for the entry of autoreactive, myelin-
specific T lymphocytes which promote tissue destruction and lead to neurological dysfunction 
(McQualter and Bernard, 2007). Therefore, enhanced barrier function of the BBB induced by 
treatment with FTY720 could help prevent the neurological symptoms associated with MS. 
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8.1.2 T Lymphocyte Model  
A T lymphocyte was modeled using the model of S1P1 with S1P1 assigned an initial 
amount of 1. While S1P4 is also expressed on T lymphocytes, there are few sources describing 
its signaling effects. The literature that discusses T lymphocyte trafficking is primarily concerned 
with S1P1 and therefore S1P4 was omitted from the T lymphocyte model.    
8.1.2.1 FTY720P Induced Aberrant Internalization of S1P1  
 Figures 10 and 11 show signaling in the T lymphocyte model treated with S1P and 
FTY720P, respectively. As seen in Figure 10, the T lymphocyte model underwent normal 
signaling when treated with 5 S1P. Figure 10 also shows that minimal AC was activated, as the 
activation of AC is inhibited by S1P1/Giα. In contrast, Figure 11 shows that S1P1 in the T 
lymphocyte model treated with 5 FTY720P was degraded, preventing signaling through S1P1. 
This is shown by the stable presence of 1 S1P1 inactivated trimeric Gi protein, meaning that Giα 
and Giβγ were not activated. The amount of activated AC increased because it was not inhibited 
by S1P1/Giα. Lastly, as a result of the differences in affinity of S1P and FTY720P for S1P1 
(Table 1), the T lymphocyte model treated with FTY720P showed a more rapid activation of 
degradation compared with a slower activation of signaling in the T lymphocyte model treated 
with S1P. 
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Figure 10. Signaling in the T lymphocyte model treated with 5 S1P. 
 
 
Figure 11. Signaling in the T lymphocyte model treated with 5 FTY720P. 
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Figure 12 shows signaling in the T lymphocyte model treated with 5 S1P and 5 
FTY720P. This graph is almost identical to the graph in Figure 11, demonstrating that FTY720P 
effectively antagonized signaling mediated by S1P. As seen in the simulations, FTY720P 
induced aberrant internalization and degradation of S1P1, which rendered T lymphocytes unable 
to respond to S1P, thereby regulating the trafficking of autoreactive, myelin-specific T 
lymphocytes that are present in MS.  
 
Figure 12. Signaling in the lymphocyte model treated with 5 S1P and 5 FTY720P. 
 
8.1.3 Endothelial Cell Model  
An endothelial cell was modeled by combining the models of S1P1 and S1P3 with S1P1 
and S1P3 assigned initial amounts of 1.  
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8.1.3.1 S1P and FTY720P Enhanced Endothelial Cell Barrier Function  
Figure 13 shows signaling in the endothelial cell model treated with 10 S1P. Rac, which 
promotes adherens junction assembly, thereby enhancing barrier function, was activated first 
through S1P1 signaling and then through S1P3 signaling. This was due to the greater affinity of 
S1P for S1P1 than for S1P3 (Table 1). Rho was not activated by S1P1; however, Rho 
accumulated by S1P3 signaling, although at a slower rate than Rac accumulated. Because S1P3 
couples more strongly to Gi than to G12/13, Rac was not inhibited.  
 
Figure 13. Signaling in the endothelial cell model treated with 10 S1P.  
 
Figure 14 shows signaling in the endothelial cell model treated with 10 FTY720P. 
Signaling in the endothelial cell model treated with 10 FTY720P occurred at an earlier time than 
signaling in the endothelial cell model treated with 10 S1P due to the increased affinity of 
FTY720P for S1P1 and S1P3 (Table 1). In the FTY720P-treated endothelial cell model, Rac was 
activated via S1P3 signaling before it was activated via S1P1 signaling. While FTY720P has a 
0
0.5
1
1.5
2
0 10 20 30 40 50
A
m
o
u
n
t
Time (seconds)
Signaling in the endothelial cell model treated with 10 S1P
S1P1/S1P
S1P3/S1P
Rac from S1P1
Rac from S1P3
Total Rac
Total Rho (from S1P3 only)
42 
greater affinity for S1P1 than for S1P3 (Table 1), S1P3 couples strongly to Gi, likely resulting in 
the initial activation of Rac from S1P3 signaling. Another difference between the signaling in the 
S1P- and FTY720P-treated endothelial cell models is that there was no accumulation of Rho in 
the endothelial cell model treated with FTY720P because FTY720P selectively activated S1P3/ 
Gi, which does not activate Rho. Rho mediates stress fiber formation and the disruption of cell 
junctions, thereby decreasing barrier function. The absence of Rho in the FYT720P-treated 
endothelial cell model may contribute to the therapeutic benefit of FTY720 treatment in MS, as it 
means that there is no competition with Rac to regulate the endothelial cell barrier. Rac enhances 
the endothelial barrier, thus regulating the egress of harmful T lymphocytes from the lymph 
nodes.  
 
Figure 14. Signaling in the endothelial cell model treated with 10 FTY720P. 
 
Figure 15 shows signaling in the endothelial cell model treated with 10 S1P and 10 
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the higher affinity of S1P for S1P1 (Table 1). Because there was a large amount of FTY720P 
bound to a limited quantity of S1P1, there was little S1P1 available for S1P to bind. In contrast, 
there was less FTY720P bound to S1P3 so there was more S1P3 available for S1P to bind. 
Therefore, Figure 15 shows more S1P3 bound to S1P (S1P3/S1P) than S1P1 bound to S1P 
(S1P1/S1P). This explanation was verified by executing a simulation with 10 S1P1 and 10 S1P3; 
as expected, there was more S1P1/S1P than S1P3/S1P (results not shown). As seen in the 
simulations, S1P and FTY720P activated Rac via S1P1 and S1P3, thereby enhancing endothelial 
barrier function.  
 
Figure 15. Signaling in the endothelial cell model treated with 10 S1P and 10 FTY720P. 
 
8.2 Astrocytes  
Astrocytes have dual roles: they can aid degeneration and demyelination by promoting 
inflammation, damage of ODCs and axons, and glial scarring (Williams et al., 2007); however, 
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injury of the CNS (Osinde et al., 2007). Additionally, astrocytes are involved in regulating the 
BBB which is damaged in MS (Abbott, 2002). Understanding the role of S1P receptor signaling 
in astrocytes, which express S1P1 and S1P3 (Mullershausen et al., 2007), can help researchers 
understand the involvement of astrocytes in the observed FTY720P-mediated neuroprotection in 
MS.  
8.2.1 cAMP Formation and ERK Phosphorylation 
FTY720P inhibits cAMP formation in astrocytes by inhibition of AC via activation of 
S1P1/Gi (Mullershausen et al., 2007). At least 1000-fold higher concentrations of S1P were 
required for comparable inhibition of cAMP formation, due to the higher affinity of FTY720P 
for S1P1 (Table 1). S1P and FTY720P also stimulate ERK phosphorylation in astrocytes via 
S1P1/Giβγ protein and S1P3/Giβγ (Osinde et al., 2006). ERK phosphorylation is involved in cell 
proliferation and survival, which may contribute to the observed FTY720P-mediated 
neuroprotection in MS. 
8.2.2 IP Levels 
In a study by Mullershausen et al. (2007), S1P (1µmol/L) maximally induced a 10-fold 
increase in inositol phosphate (IP) levels, which was dependent on S1P1/Gi and to a lesser 
extent, S1P3/Gi and S1P3/Gq. In contrast, FTY720P (100nmol/L), maximally induced a four-fold 
increase in IP levels, which involved activation of S1P1/Gi and to a lesser extent, S1P3/Gi. 
FTY720P selectively induces activation of S1P3/Gi signaling while inhibiting S1P-induced 
activation of S1P3/Gq signaling (Sensken et al., 2008) thus explaining the involvement of only 
S1P1/Gi and S1P3/Gi in the increase in IP levels due to FTY720P. Additionally, IP is formed 
through the activation of PLC, which is generally linked to α subunits of Gq proteins. While PLC 
activation also occurs via the βγ subunits of Gi proteins, a higher number of activated receptors 
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and higher concentrations of βγ subunits are required for this activation (Birnbaumer, 1992), 
which may explain the smaller increase in IP levels after treatment with FTY720P than after 
treatment with S1P.  
8.2.3 Astrocyte Migration 
FTY720P also promotes astrocyte migration (Mullershausen et al., 2007). Both S1P1 and 
S1P3 activation have been shown to promote cell migration, whereas S1P2 activation inhibits 
migration (Okamoto et al., 2000). FTY720P does not act on S1P2 and is a partial agonist on 
S1P3, suggesting that FTY720P promotes astrocyte migration primarily via signaling through 
S1P1. Additionally, FTY720P and S1P1-selective agonist SEW2871 promoted astrocyte 
migration to a similar extent (Mullershausen et al., 2007), further suggesting that it is primarily 
S1P1 receptors that are activated by FTY720P to promote astrocyte migration. Rac, which is 
activated by S1P1/Giβγ signaling, and to a lesser extent, S1P3/Giβγ signaling, plays an important 
role in cellular migration by directing peripheral actin assembly, resulting in the formation of 
lamellipodia at the leading edge of the cell (Sugimoto et al., 2003). FTY720P does not activate 
Rho, which inhibits migration, because it does not activate S1P3/G12/13. Astrocyte migration into 
regions of brain injury is involved in glial scar formation and may act as a mechanical barrier to 
axonal regeneration (Lim et al., 2007), suggesting that the actions of FTY720P on astrocytes 
could actually be harmful in MS. Nonetheless, it is still important to understand these actions, as 
understanding what is beneficial or harmful in MS could help researchers optimize MS 
treatments.  
8.2.4 Astrocyte Model  
An astrocyte was modeled by combining the models of S1P1 and S1P3 with S1P1 and 
S1P3 assigned initial amounts of 1.  
46 
8.2.4.1 S1P and FTY720P Inhibited cAMP Formation  
 Figure 16 shows the percent inhibition of AC and the percent of cAMP formation (based 
on the amount of available ATP to be converted into cAMP) as a function of the initial amounts 
of S1P or FTY720P in the astrocyte model. Activation of AC and consequently, cAMP 
formation, were inhibited starting at approximately 1 FTY720P, whereas comparable inhibition 
required approximately 3-4 S1P. While these values did not replicate the quantitative data 
determined by Mullershausen et al. (2007), they do follow the trend described in Mullershausen 
et al. (2007), that is, that FTY720P is a significantly stronger inhibitor of AC than S1P.  
  
Figure 16. Percent inhibition of AC (left) and percent cAMP formation (right) after 100 seconds as a function of 
initial amounts of S1P or FTY720P in the astrocyte model. 
 
8.2.4.2 S1P and FTY720P Stimulated ERK Phosphorylation 
Figure 17 shows the accumulation of phosphorylated ERK in the astrocyte model treated 
with 15 S1P. As seen, the amount of phosphorylated ERK increased first due to the activation of 
S1P1/Gi and second, due to the activation of S1P3/Gi. Because S1P has a lower affinity for S1P3 
than for S1P1 (Table 1), S1P activated S1P1 more quickly than it activated S1P3.  
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Figure 17. Phosphorylation of ERK in the astrocyte model treated with 15 S1P.  
 
As seen in Figure 17, FTY720P also induced ERK phosphorylation in the astrocyte 
model. A much smaller amount of FTY720P was required to induce ERK phosphorylation at a 
similar time scale as in the S1P-treated astrocyte model, due to the higher affinity of FTY720P 
for S1P1 and S1P3 (Table 1). Like S1P, FTY720P has a greater affinity for S1P1 than for S1P3 
(Table 1) and thus the amount of phosphorylated ERK increased first due to the activation of 
S1P1/Gi and second, due to the activation of S1P3/Gi. The results from this simulation agreed 
with results from the literature, demonstrating that S1P and FTY720P activated S1P1/Gi and 
S1P3/Gi signaling in astrocytes to stimulate the phosphorylation of ERK. 
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Figure 17. Phosphorylation of ERK in the astrocyte model treated with 3 FTY720P. 
 
8.2.4.3 S1P and FTY720P Stimulated PLC Activation and IP3 Formation  
Figure 18 shows PLC activation and IP3 formation in the astrocyte model treated with 5 
S1P. PLC was activated by S1P1/Giβγ, S1P3/Giβγ, and S1P3/Gqα. Because S1P has a greater 
affinity for S1P1 than for S1P3 (Table 1), a greater amount of S1P1/Gi was activated than 
S1P3/Gi or S1P3/Gq within the time scale shown.  
PLC activation, and consequently IP3 formation are usually mediated by Gqα. While PLC 
activation also occurs via the βγ subunits of Gi proteins, a higher number of activated receptors 
and higher concentrations of βγ subunits are required for this activation (Birnbaumer, 1992); 
therefore, although there was a smaller amount of S1P3/Gqα than S1P1/Giβγ, PLC was initially 
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followed that IP3 was formed initially by signaling via S1P3/Gqα, next by signaling via 
S1P1/Giβγ, and finally by signaling via S1P3/Giβγ.  
 
Figure 18. PLC activation and IP3 formation in the astrocyte model treated with 5 S1P.  
  
The FTY720P-mediated responses of PLC activation and IP3 formation differed from 
those of S1P. When the astrocyte model was treated with 5 FTY720P, as seen in Figure 19, S1P1 
and S1P3 were activated more quickly than when treated with S1P, as FTY720P has a greater 
affinity than S1P for S1P1 and S1P3 (Table 1). Because the model reached equilibrium within 50 
seconds of treatment, the simulation is only shown for 50 seconds, whereas the simulation of the 
astrocyte model treated with S1P is shown for 300 seconds.  
FTY720P selectively activates S1P3/Gi (Sensken et al., 2008); therefore, PLC was only 
activated via S1P1/Gi and S1P3/Gi. Consequently, no IP3 was formed through activation of 
S1P3/Gq and the total amounts of PLC and IP3 in the model astrocyte treated with FTY720P 
were less than in the model astrocyte treated with S1P. This trend agreed with results described 
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in the literature, which state that FTY720P maximally induced a four-fold increase in IP levels, 
whereas S1P maximally induced a 10-fold increase in IP levels (Mullershausen et al., 2007). The 
selective activation of S1P3/Gi by FTY720P as seen in the simulation also agrees with results 
described in the literature, which state that the increase in IP levels due to FTY720P was largely 
sensitive to PTX (Mullershausen et al., 2007).  
 
Figure 19. PLC activation and IP3 formation in the astrocyte model treated with 5 FTY720P.  
 
8.2.4.4 S1P and FTY720P Promoted Astrocyte Migration  
Figure 20 shows the accumulation of activated Rac and Rho in the model astrocyte 
treated with 5 S1P. Rac was activated initially and primarily via signaling through S1P1/Gi. Rac 
continued to accumulate from S1P3/Gi; however, due to S1P’s lower affinity for S1P3 than for 
S1P1 (Table 1), S1P3 was activated much more slowly and therefore the contribution of Rac 
from S1P3 was less significant. Additionally, Rho was activated in the model astrocyte via 
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S1P3/G12/13, although at a later time. Because S1P3 couples more strongly to Gi than to G12/13, 
Rho was unable to inhibit Rac, and therefore S1P promoted astrocyte migration.  
 
Figure 20. Activation of Rac and Rho in the astrocyte model treated with 5 S1P.  
 
Figure 21 shows the accumulation of activated Rac and Rho in the model astrocyte 
treated with 5 FTY720P. Rac was activated initially and primarily via signaling through S1P1/Gi, 
though it continued to accumulate to a lesser extent via signaling through S1P3/Gi. Rho was not 
activated because FTY720P selectively activates the Gi protein of S1P3 (Sensken et al., 2008) 
and does not activate S1P3/G12/13. Therefore, it is likely that FTY720P promotes astrocyte 
migration to a greater extent than S1P does, as there was no competition with Rac to regulate cell 
migration.  
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Figure 21. Activation of Rac and Rho in the astrocyte model treated with 5 FTY720P.  
 
8.3 OPCs  
In MS, inflammatory damage to myelin and ODCs causes demyelination in the CNS, 
disrupting the transmission of electrochemical messages along the nerves. Remyelination of MS 
lesions, which involves restoring demyelinated axons with new myelin sheaths, contributes to the 
recovery from MS attacks. Data from experimental models of CNS demyelination suggest that 
remyelination is dependent on OPCs. Microglia and astrocytes are activated in response to 
demyelination and injury and induce the activation and proliferation of OPCs, which migrate to 
demyelinated areas in the recruitment phase of remyelination (Franklin and ffrench-Constant, 
2008). Following recruitment, OPCs differentiate into ODCs in the final step of remyelination, 
which involves axon engagement and myelin sheath formation. Remyelination restores 
conduction along the nerves, resolving the symptoms associated with MS attacks. Unfortunately, 
remyelination is often inadequate in MS and is eventually responsible for the progressive 
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disability associated with MS (Franklin and ffrench-Constant, 2008). Understanding the role of 
S1P receptor signaling in OPCs can help researchers understand the involvement of OPCs in 
remyelination and in the observed FTY720P-mediated neuroprotection in MS. 
8.3.1 OPC Migration and Differentiation 
Three S1P receptors are found in human OPCs in the following order of expression: S1P1 
> S1P5 > S1P3 (Miron et al., 2008b). A study by Miron et al. (2008b) showed that short term 
FTY720P treatment of human OPCs caused initial process retraction via S1P5-mediated 
activation of Rho, resulting in the inhibition of OPC migration and differentiation. The inhibition 
of OPC migration and differentiation was not sensitive to PTX, indicating that Gi was not 
involved (Novgorodov et al., 2007).   
While process extension is required to some extent for remyelination, process retraction 
is necessary for terminal ODC differentiation (Solly et al., 1996 as cited by Miron et al., 2008). 
Terminal differentiation of the ODC involves a reduction in the number of processes, 
transferring the OPC into a myelinating ODC with a few primary processes. The myelination 
process consists of the enwrapping of each axon segment by a single ODC extension. Therefore, 
it is possible that the number of processes is reduced to match the number of axonal segments in 
need of myelination (reviewed in Jaillard et al., 2005). 
Short term treatment with S1P or FTY720P causes an initial down-regulation of S1P5, 
followed by up-regulation of S1P1 (Novgorodov et al., 2007; Miron et al., 2008; and Jung et al., 
2007). According to Jung et al. (2007), platelet-derived growth factor (PDGF) up-regulates the 
expression of S1P1 and down-regulates S1P5 by an unknown mechanism which likely involves 
cross-talk between PDGF- and S1P-mediated signaling. Cross-talk is the influence of activation 
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of one receptor type on signaling through a second receptor type (Linderman, 2009). Due to the 
complexity associated with cross-talk, these effects were not included in the model.  
Continued treatment with S1P or FTY720P induced process extension via S1P1-mediated 
activation of Rac (Jung et al., 2007) and enhanced OPC survival via S1P1-mediated activation of 
ERK and Akt (Miron et al., 2008b; Coelho et al., 2007).   
8.3.2 OPC Model  
An OPC was modeled by combining the models of S1P1, S1P3, and S1P5 with S1P1, 
S1P3, and S1P5 assigned initial amounts of 0, 0.5, and 1 respectively. S1P1 was assigned an 
initial amount of 0 to model the up-regulation of S1P1 following the down-regulation of S1P5. 
To model this, an event was introduced at five seconds that changed the amount of S1P5 to 0 and 
the amount of S1P1 to 1.   
8.3.2.1 S1P and FTY720P Modulated OPC Migration and Differentiation 
Figure 22 shows signaling in the OPC model treated with 15 S1P. Phosphorylated ERK 
and activated Rho associated with S1P3 signaling were not shown in the graph because they 
were activated around 800 seconds. As seen in Figure 22, Rho was activated first, via S1P5 
signaling. Rho is associated with process retraction and the inhibition of OPC differentiation. 
Next, as S1P5 was down-regulated and S1P1 was up-regulated at five seconds, S1P1 signaling 
through Giβγ activated Akt and ERK simultaneously; these species enhance cell survival. Shortly 
after, Rac was also activated via S1P1/Giβγ signaling. Rac is associated with cell migration and 
process extension (Miron et al., 2008b).  
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Figure 22. Signaling in the OPC model treated with 15 S1P.  
 
S1P3 was not involved in OPC process extension, differentiation, or survival, likely due 
to the relatively low abundance of S1P3 in OPCs and the low affinity of FTY720P and S1P for 
S1P3 (Table 1). Likewise, results from the literature do not associate S1P3 with the signaling 
events that occur in OPCs. Because S1P and FTY720P activate S1P1 and S1P5 similarly and 
because S1P3 signaling is not significant in the OPC model, the same signaling events occurred 
when the OPC model was treated with FTY720P as when it was treated with S1P; however, less 
FTY720P was required to achieve a similar activation of events (Figure 23).  
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Figure 23. Signaling in the OPC model treated with 5 FTY720P.  
 
With the inclusion of the event down-regulating S1P5 and up-regulating S1P1, the OPC 
model was able to reproduce results described in the literature, which state that short term 
treatment of OPCs with S1P or FTY720P causes initial process retraction via S1P5-mediated 
activation of Rho, and that continued treatment of OPCs with S1P or FTY720P causes process 
extension via S1P1-mediated activation of Rac and enhanced cell survival via S1P1-mediated 
activation of Akt and ERK (Miron et al., 2008b).  
 
9. Conclusion 
 The creation of the S1P receptor and cell type models allowed collections of reported 
observations to be integrated into qualitative computational models. These models should help 
researchers to understand the signaling events transduced through the S1P receptors due to 
activation by the endogenous sphingolipid, S1P, or the novel, orally-available 
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immunomodulator, FTY720P. Understanding the actions of the prodrug, FTY720, is particularly 
important, as FTY720 is currently being tested in Phase III clinical trials for the treatment of MS. 
FTY720 is phosphorylated in vivo to become FTY720P, which is a potent agonist on four out of 
the five S1P GPCRs: S1P1, S1P3, S1P4, and S1P5. The drug’s primary mechanism of action is 
the regulation of T lymphocyte trafficking, which involves the internalization and degradation of 
S1P1 on T lymphocytes and an enhanced endothelial barrier via S1P1- and to a lesser extent, 
S1P3-mediated signaling on endothelial cells. As a result of the regulation of T lymphocyte 
trafficking, T lymphocytes are sequestered in the lymph nodes, preventing the entry of 
autoreactive, myelin-specific T lymphocytes into the CNS.   
 FTY720P also exerts direct effects in the CNS. For example, FTY720P acts on the S1P 
receptors on astrocytes to activate ERK, inhibit cAMP formation, induce IP formation, and 
induce migration. In OPCs, FTY720P is involved in process extension and retraction, 
differentiation, survival, and migration. The roles of S1P and FTY720P in lymphocyte 
trafficking and in the CNS are still far from being fully understood. Consequently, the S1P 
receptor and cell type models will continue to be improved as more research is published 
presenting a better understanding of the signaling events involved in S1P- and FTY720P- 
mediated S1P receptor signaling. While the S1P receptor and cell type models were not perfect 
in a quantitative sense, they succeeded in qualitatively reproducing events described in the 
literature and can provide an in silico workbench by which researchers can investigate these 
actions outside of the lab. 
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10. Future Directions 
In addition to updating the S1P receptor and cell type models to incorporate the results of 
new research as it becomes available, there are other ways in which the models could be 
improved. For example, modeling the cross-talk between S1P and the PDGF receptor could 
improve understanding of the signaling associated with S1P1 up-regulation and S1P5 down-
regulation in OPCs. Cross-talk has also been observed between S1P and the PDGR receptor 
mediated by S1P3 (Baudhuin et al., 2004) and between S1P and vascular endothelial growth 
factor (VEGF) receptor-2 (Spiegel and Milstien, 2003). The inclusion of cross-talk in the cell 
type models could help researchers to more fully investigate the signaling events transduced by 
the S1P receptors.  
Furthermore, there are additional ways in which the models can be utilized. Here, the S1P 
receptor and cell type models were used to investigate the effects of treatment with S1P or 
FTY720P in cell types that are involved in the pathogenesis of MS. However, many other S1P 
receptor agonists have been identified. One such agonist, KRP-203, has a similar affinity for 
S1P1 as FTY720P does, but has a much lower affinity for S1P3. As a result, a common side 
effect associated with treatment with FTY720, S1P3-dependent bradycardia, would be reduced 
upon treatment with KRP-203 (Huwiler and Pfeilshcifter, 2008). Other autoimmune or 
neurodegenerative diseases could also be investigated using the models, as the S1P receptors are 
not unique to patients with MS. FTY720P is already being researched as an option for the 
treatment of various other diseases including asthma (Idzko et al., 2006) and lupus (Ye et al., 
2007). 
  In addition, more cell type models could be constructed. Certain cell types, such as 
gastrointestinal smooth muscle cells (GSMCs) and vascular smooth muscle cells (VSMCs) were 
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not modeled because they were not directly relevant to the effects of FTY720 in the treatment of 
MS. However, models of these cell types could be useful to understand the effects of FTY720 for 
other conditions or to explain side effects associated with FTY720 use; for example, the transient 
bradycardia caused by the actions of FTY720P on cardiac S1P3 receptors (Takabe et al., 2008).   
Hopefully, the S1P receptor and cell type models will be useful tools for other 
researchers of S1P receptor signaling when investigating the effects of treatment with FTY720P 
or other S1P agonists in MS or other diseases. Additionally the inclusion of new in vitro and in 
vivo research in the models can allow for a more comprehensive understanding of S1P receptor 
signaling. Ultimately, testing FTY720P or other S1P agonists in the S1P receptor and cell type 
models should prove to be a valuable investigative approach before spending time and money to 
perform in vitro or in vivo tests. 
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